Study title: Persistence of anti−hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half−life. Leenen FH, Fourney A, Notman G, Tanner J. British journal of clinical pharmacology, Feb 1996, vol. 41, no. 2, p. 83−8Persistence of anti−hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half−life. Leenen FH, Fourney A, Notman G, Tanner J. British journal of clinical pharmacology, Feb 1996, vol. 41, no. 2, p. 83−8
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases [C14] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: DILTIAZEM | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |